文献速递神经头颈CTMRPET

混合[18F]氟雌二醇脑PET/CT/MRI与MRI及顶点至膝下PET成像检测雌激素受体阳性颅内转移瘤的比较

Hybrid [18F] Fluoroestradiol Brain PET/CT/MRI for Detection of Estrogen Receptor-Positive Intracranial Metastases Compared with MRI and Vertex-to-Below the Knees PET Imaging.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-10-01

本研究回顾性分析10例ER阳性乳腺癌女性患者的90个脑及颅骨转移灶,比较混合[18F]FES脑PET/MRI与增强脑MRI及顶点至膝下[18F]FES PET/CT的检出差异;混合[18F]FES脑PET/MRI检出12个增强MRI未显示的病灶,并改变了9/10例患者的临床管理决策。

要点

  • 混合[18F]FES脑PET/MRI可检出增强脑MRI未显示的13.3%(12/90)病灶。
  • 颅骨转移灶中42.1%(8/19)仅被[18F]FES脑PET/MRI检出而MRI未显示。
  • 顶点至膝下[18F]FES PET/CT遗漏17.8%(16/90)脑PET/MRI可见病灶。

核心结论

  • 将[18F]FES脑PET/CT/MRI整合入临床工作流程,提高了ER阳性病灶的检出率,并对临床管理决策产生了实质性影响。

研究设计与样本

  • 经机构审查委员会批准的回顾性分析,纳入2024年1月至2024年11月在本机构接受[18F]FES脑PET/CT及增强脑MRI的患者10例(女性,ER阳性乳腺癌,平均年龄64.3岁,SD 7.5)。

关键影像表现/征象

  • 90个脑及颅骨转移灶中,12个(13.3%)在增强脑MRI上隐匿,由[18F]FES脑PET/MRI检出,包括1个脑实质病灶、8/19(42.1%)颅骨病灶和5/6(50.0%)颅外软组织/头皮病灶。
  • 与[18F]FES脑PET/MRI相比,顶点至膝下[18F]FES PET/CT遗漏16/90(17.8%)病灶,包括13/58(22.4%)脑实质病灶和3/7(42.9%)硬脑膜based病灶。

诊断标准与关键数值

  • 由专家神经放射科医师使用融合[18F]FES脑PET/MRI分析颅内病灶(包括脑实质、硬脑膜based、颅骨、软脑膜及颅外软组织/头皮),记录病灶大小、位置和最大标准摄取值。
  • 两名放射科住院医师独立审阅增强脑MRI报告并记录颅内病灶数量和位置。
  • 核医学科医师审阅顶点至膝下[18F]FES PET/CT并报告颅内病灶数量和最大标准摄取值。

临床应用与阅片要点

  • 将[18F]FES脑PET/CT/MRI整合入临床工作流程可提高ER阳性脑及颅骨转移灶的检出。
  • 在[18F]FES脑PET/MRI后,9/10例患者(90%)的临床管理决策发生改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: [18F]-fluoroestradiol (FES) is a novel molecular imaging radiopharmaceutical that has demonstrated promise in the staging of ER-positive brain metastases. Our aim was to determine if hybrid [18F] FES brain PET/MRI is superior to conventional brain MRI alone for detecting estrogen receptor (ER)-positive brain and calvarial metastases, compare limited [18F] FES brain PET with vertex-to-below the knees [18F] FES PET results, and determine the impact of [18F] FES brain PET/MRI on patient management decisions.

MATERIALS AND METHODS: Following institutional review board approval, a retrospective analysis was conducted of patients who underwent [18F] FES brain PET/CT and contrast-enhanced brain MRI at our institution from January 2024 to November 2024. Intracranial lesions, including parenchymal, dural-based, calvarial, leptomeningeal, and extracranial soft tissue/scalp, were analyzed by an expert neuroradiologist using fused [18F] FES brain PET/MRI, and lesion size, location, and maximum standard uptake value were recorded. Two radiology residents reviewed separately acquired contrast-enhanced brain MRI reports and documented the number and location of intracranial lesions. A nuclear medicine physician reviewed vertex-to-below the knees [18F] FES PET/CT and reported the intracranial lesion number and maximum standard uptake value.

RESULTS: Ten female patients with ER-positive breast cancer with 90 metastatic brain and calvarial lesions were included in our analysis. The mean age was 64.3 (SD, 7.5) years. Twelve of 90 (13.3%) lesions were occult on contrast-enhanced brain MRI but detected by 18F-FES brain PET/MRI, including 1 parenchymal lesion, 8/19 (42.1%) calvarial lesions, and 5/6 (50.0%) extracranial soft-tissue/scalp lesions. Meanwhile, 16/90 (17.8%) lesions were occult on vertex-to-thigh 18F-FES PET/CT compared with [18F] FES brain PET/MRI, including 13/58 (22.4%) parenchymal lesions and 3/7 (42.9%) dural-based lesions. There was a modification in patient management for 9 of 10 patients (90%) following the [18F] FES brain PET/MRI.

CONCLUSIONS: By integrating [18F] FES brain PET/CT/MRI into our clinical workflow, we improved the detection of ER-positive lesions, resulting in a substantial impact on clinical management decisions.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Mashriqi F, Chen M, Keir G, et al. Hybrid [18F] Fluoroestradiol Brain PET/CT/MRI for Detection of Estrogen Receptor-Positive Intracranial Metastases Compared with MRI and Vertex-to-Below the Knees PET Imaging. AJNR Am J Neuroradiol. 2025. PMID: 40968016. doi:10.3174/ajnr.A8863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。